Gastrointestinal Cancer News

Robotic liver dissection appeared safe and effective compared with open liver resection among patients with hepatocellular carcinoma, according to study results published in JAMA Surgery.

The addition of pembrolizumab to chemotherapy improved OS among certain patients with gastric or gastroesophageal junction cancers, according to the agent’s manufacturer.

Use of different antibody-drug conjugates resulted in a variety of significant and in some cases serious treatment‐associated adverse events, according to results of a systematic review and meta-analysis published in Cancer.

Maheswari Senthil, MD, FACS — chief of surgical oncology at University of California, Irvine — has been named John Wayne Cancer Foundation endowed chair in surgical oncology.

The FDA granted orphan drug designation to ZB131 for treatment of cholangiocarcinoma, according to the agent’s manufacturer.

More than 2 years after the COVID-19 pandemic began, new treatments, vaccines and preventive measures have improved safety and disease outcomes for patients with cancer, according to a speaker at Chemotherapy Foundation Symposium.

The addition of zolbetuximab to chemotherapy improved PFS among certain patients with gastric or gastroesophageal junction cancers, according to the agent’s manufacturer.

CHARLOTTE, N.C. — Recommended surveillance interval was the most important modifiable risk factor for post-colonoscopy colorectal cancer at 3 years, according to research presented at the ACG Annual Scientific Meeting.

The first personalized cellular therapy to use gene replacement for treatment of cancer has shown to be safe in solid tumors, data from a phase 1 study published at Society for Immunotherapy of Cancer Annual Meeting showed.

An irinotecan liposome injection regimen improved OS compared with standard chemotherapy among untreated patients with metastatic pancreatic ductal adenocarcinoma, according to the agent’s manufacturer.